klinische complicaties bij acute en chronische virale hepatitis...
TRANSCRIPT
Klinische complicaties bij acute en
chronische virale hepatitis
K.J. van Erpecum
Complicaties acute virale
hepatitis
Wat staat oa in de DD bij AST en/of ALT > 1000 IU/mL
Alcohol hepatitis altijd relatief lage transaminasen: AST<500, ALT<250
Belangrijkste oorzaken: paracetamol, ischemische hepatitis, viraal,
choledocholithiasis.
Medicamenteus, homeopathie, kruiden
autoimmuun hepatitis,
10% van choledocholithiasis transen > 1000IU/mL in eerste 48 uur
Acuut leverfalen
Worm et al. Microbes and Infection 2002
▪ Zeldzaam ziektebeeld
▪ Hoge mortaliteit
▪ Kenmerken:
▪ Gestoorde stolling (INR > 1.5)
▪ Hepatische encefalopathie
▪ Geen onderliggende leverziekte
▪ Duur ziekte < 24 weken
▪ Uitsluiten van acute-on-chronic liver failure
Polsen J,Lee WM , Hepatology 2005; O’Grady JG et al. Lancet 1993, Trey
C and Davidson CS, Prog Liver Dis. 1970
Klinische presentatie
Worm et al. Microbes and Infection 2002
▪ Acuut ziektebeeld
▪ +/- na inname van paracetamol / amanita / XTC
etc.
▪ Buikpijn, malaise, ziek, verward
▪ Icterus
▪ Hoge transaminasen
▪ Gestoorde stolling
▪ Progressief beeld met oligurie, metabole acidose,
hypotensie
Hepatische encefalopathie: voorwaarde voor het stellen
van de diagnose
Incidentie en oorzaak van ALF
▪ Europa en US: 1-6/miljoen/jaar
▪ Afhankelijk van werelddeel
Europa & US
1.DILI2.Viraal (A,B,E)3.Onbekend4.AIH5.Ischemisch6.Wilson7.Budd-Chiari8.…
Ontwikkelingslanden
1.Viraal (E,B,A)2.Onbekend3.DILI4.….
Korman. Hepatology 2008;48:1167-74
Alkaline phosphatase/bilirubin ratio <4 very specific and sensitive for
diagnosing Wilson disease in acute liver failure (bili in mg/L).
Acuut leverfalen en kans op overlijden
Worm et al. Microbes and Infection 2002
▪ Afhankelijk van presentatie en oorzaak
▪ Gemiddelde kans: 30 %
▪ Belangrijkste oorzaken van overlijden:
▪ Sepsis /Infectie
▪ Multi-orgaan falen
▪ Hersenoedeem/ inklemming
▪ Bloeding
Diagnostiek bij ALF
▪ Infuus met glucose 5 %
▪ PPI
▪ Antibiotica
▪ N-acetylcysteïne (NAC)
▪ Monitoring van ademhaling, bewustzijn, circulatie, nierfunctie,
leverfuncties, stolling, infectie etc.
Eerste opvang bij patiënt met ALF
▪ Opname op intensive care
▪ Oorzakelijke behandeling (NAC, bevalling, lamivudine,
steroïden)
▪ Intubatie bij HE graad 3 of 4
▪ Herstel van circulatie (MAP > 65 mm Hg)
▪ Voorkomen en behandelen van complicaties
Behandeling van acuut leverfalen
➢Pre-emptief starten met antibiotica en
antimycotica
Behandeling van acuut leverfalen
➢Geen stollingscorrectie, tenzij ….
Behandeling van acuut leverfalen
Lisman T et al. J Hepatol 2010
Lisman T et al. J Thromb Haemost 2012
Ganey P et al Hepatology 2007
Bernal W et al. Hepatology 2007
•Neurologische complicaties :
• hersenoedeem
• intracraniale hypertensie
• Pathogenese : circulerende neurotoxinen
• Incidentie Hersenoedeem & ICH
• graad 1 & 2 : zeldzaam
• graad 3 : 25-35%
• graad 4 : 65-75%
• Regelmatig klinisch neurologisch onderzoek
• Biochemische parameter : arterieel NH3
NH3 < 100 µmol/L: zelden ICP
NH3 > 100 µmol/L ~ ICP
Het grote gevaar: hersenoedeem
Bepalen van prognose
Either:
• PT > 100s (INR > 6.5)(encephalopathy present but irrespective of grade)
or
• Any 3 of the following(encephalopathy present but irrespective of grade)
• patient age < 10 or > 40 years
• serum bilirubin > > 300 umol/L
• time jaundice to HE > 7 days
• PT > 50s (INR > 3.5)
• etiology: non hepatitis A/B or drug-
induced
NON-PARACETAMOL
INDUCED ALF
O’Grady J et al. Gastroenterology 1989
Either:
• arterial pH < 7,3 following adequate volume resuscitation and irrespective of HE grade
or
• all 3 of the following criteria
• HE grade III-IV
• PT > 100s (INR > 6.5)
• serum creatinin > 300 umol/L
PARACETAMOL
INDUCED ALF
KING’S COLLEGE HOSPITAL CRITERIA FOR TX IN ALF (KCC)
Complicaties chronische virale
hepatitis
Colombo et al. Hepatology 2006;43:1303-10
Cumulative probability of liver-related events in patients
with compensated cirrhosis due to hepatitis C
varices
Therapy varices: beta blockers and/or
endoscopic band ligation
Small varices Large varicesNo varices
7-8%/year 7-8%/year
Varices may Increase in Diameter Progressively
Merli et al. J Hepatol 2003;38:266
VARICES INCREASE IN DIAMETER PROGRESSIVELY
Prophylaxis of Variceal Hemorrhage
Diagnosis of Cirrhosis
Endoscopy
No Varices
Follow-up EGD in 2-3 years*
Small Varices
Follow-up EGD in 1-2 years*
Medium/Large Varices
•Stepwise increase until maximally tolerated dose•Continue beta-blocker (life-long)
No Contraindications
ContraindicationsorBeta-blocker intolerance
Beta-blocker therapy
Endoscopic Variceal Band Ligation
*EGD every year in decompensated cirrhosis
MANAGEMENT ALGORITHM FOR THE PROPHYLAXIS OF VARICEAL HEMORRHAGE - SUMMARY
Primary prophylaxis for variceal bleeding
• NSBB: Propranolol, starting dose 10 mg BID
• Endoscopic follow-up in patients with primary prophylaxis
with NSBB is unnecessary
• In patients who have contraindications to NSBB → EVL.
de Franchis. J Hepatology 2010
• Wat is het streef Hb bij varix bloeding?
A) 4,2 mM
B) 5 mM
C) 6 mM
D) 7 mM
Restrictive (4.3 mM) vs liberal transfusion
(5.6 mM) strategy for acute GI bleeding
Villanueva et al. New Engl J Med January 3, 2013
Villanueva et al. New Engl J Med January 3, 2013
Restrictive (4.3 mM) vs liberal transfusion (5.6 mM)
strategy for acute GI bleeding
Secondary profylaxis of variceal bleeding
Ascites
Leuco dif:
lymphocytosis!!
Therapeutic considerations ascites :
• sodium restriction (5 g NaCl/2 g Na+/88 mMol Na+)
• aldactone 100 mg + furosemide 40 mg (cave hyperkalemia, especially in diabetics/renal insufficiency)
• Measure:
– weight loss (<0.5-1 kg/day: if significant edema faster weight loss allowed)
– 24 hrs urinary Na+ and creatinin excretion (or Na+ / K+ ratio in spot urine)
– Alternative: large volume paracentesis, TIPS
• An cirrhotic ascites patient is treated with dietary sodium
restriction, aldactone 200 mg, furosemide 60 mg, but ascites
does not decrease and weight tends to increase. Laboratory
results: serum Na+ 127 mM, K+ 5.3 mM, creat 138 mM, 24 hr
urinary Na+ excretion 160 mMol: Your conclusion is
– A) diuretic resistance due to impending hepatorenal
syndrome
– B) patient not compliant to instituted therapy, needs further
counselling
– C) patient needs water restriction
– D) diuretic dosage should be increased
– E) large volume therapeutic paracentesis is indicated.
Spontaan bacteriele peritonitis
Diagnosis of SBP:
– EDTA tube: ascites granulocytes >0.25x109/L, with or without positive culture
• Clotting disorders no contraindication to diagnostic puncture
• Ascites leuco dif (automatic count in edta vial)
– bedside inoculation aerobic/anaerobic blood culture bottles (>10 mL)
– In case of granulocytes >0.25x109/L: consider additional blood cultures (low yield of ascites culture).
Rimola. J Hepatol 2000;32:142-53
Additional albumin reduces mortality in
spontaneous bacterial peritonitis
• Rodes et al. New Engl. J. Med. 1999;341:403-9
– 126 SBP pt randomized for cefotaxim + albumin
– albumin 1,5 g/kg on day 1: 1 g/kg on day 3
Post-hoc analysis: albumin benefits subgroups of
SBP patients with high bili/renal insufficiency
• Benefit albumin in subgroups of spontaneous
bacterial peritonitis patients with:
– bili > 70 uMol/L
– creatinin > 110 uMol/L
Spontaneous bacterial peritonitis: prophylaxis
• After first episode of SBP
– secondary prophylaxis with norfloxacin 400 mg/day
• often emergence gram-positive quinolone resistant
microorganisms.
• Stop if ascites disappears!
Hepatorenaal syndroom
International Ascites Club, Hepatology 1996
HEPATORENAL SYNDROMECLINICAL TYPES
Type 1
- Rapidly progressive renal failure:
- Clinical presentation: acute renal failure
- Often in setting of infection (SBP)
Type 2
- Stable/gradually progressive renal failure
- Clinical setting: refractory ascites
SURVIVAL IN THE DIFFERENT TYPES OF HEPATORENAL SYNDROME (HRS)
0 2 4 6 8 1210
Months
1
0.2
0.4
0.6
0.8
Survival
probability
0
Type 2
p = 0.001
Survival in Different Types of Hepatorenal Syndrome (HRS)
Gines et al., Lancet 2003; 362:1819
Type 1
TREATMENT OF HEPATORENAL SYNDROME
VASOCONSTRICTOR DRUGS
Vasopressin analogues
- Terlipressin + albumin
- Ornipressin
Alfa-adrenergic agonists
- Norepinephrine
- Midodrine
Other- Octreotide
HEPATORENAL SYNDROMETERLIPRESSIN. RESPONSE TO TREATMENT
Terlipressin + albumin
Albumin Placebo + albumin
0
20
40
60
80
100
Re
sp
on
se
(%
)
TAHRS trial* North American trial**
44%
9%
34%
13%
p=0.017 p=0.008
* Martín-LLahí M et al., EASL 2007
** Sanyal A et al., AASLD 2006
N:45 N:112
• History of coronary artery disease
• Dilated and non-dilated cardiomyopathies
• Cardiac arrithmias
• Cerebrovascular disease
• Obliterative arterial disease of lower limbs
• Hypertension
• Asthma, chronic obstructive pulmonary disease
• Age > 70 years
Contraindications to terlipressin use (15%
complication rate in various studies)
Lebrec. Hepatol 2006;43:385-94
Various forms of renal insufficiency:
ends of a spectrum
PrerenalHepatorenal
syndrome
Acute tubular
necrosis
Volume expansion
(albumin)
Terlipressin +
albumin
Dialysis?
Some clues to differentiate between hepatorenal syndrome type 1 (responsive)
and acute tubular necrosis (non-responsive)
HRS type 1 Acute tubular
necrosis
Recent shock no frequent
Recent nephrotoxic drugs no frequent
Fractional Na+ excretion * <1% >1%
Fractional Ureum excretion: ATN >33% /
prerenal 21-33% /HRS <21%
((HEPATOLOGY 2018;68:224-233)
* urine Na+ /serum Na+
urine creat /serum creat X 100Lebrec. Hepatol 2006;43:385-94
Hepatic encephalopathy
Lactulose remains first line therapy for hepatic encephalopathia
51
Resultaten (3)
52
Conclusie
• Rifaximin verlaagt het risico op ontstaan van HE in combinatie met lactulose
• Rifaximin in combinatie met lactulose is effectiever dan lactulose als monotherapie
• Vermindert het aantal ziekenhuisopnames
53
Rifaximin and driving performance in minimal hepatic
encephalopathia
Hepatocellular carcinoma
Surveillance for hepatocellular carcinoma
Ultrasound every 6 months with or without alfa fetoprotein
Population group
Cirrhosis
Threshold incidence for efficacy
of surveillance
(%/year)
Incidence of HCC
Hepatitis B cirrhosis 0.2-1.5 3-8%/yr
Hepatitis C cirrhosis 1.5 3-5%/yr
Hemochromatosis cirrhosis 1.5 3-4%/year
Alcoholic cirrhosis 1.5 probably >1.5%/year
Stage 4 primary biliary cirrhosis 1.5 3-5%/yr
No cirrhosis
Asian male hepatitis B carriers over
age 40
0.2 0.4-0.6%/year
Asian female hepatitis B carriers over
age 50
0.2 0.3-0.6%/year
Hepatitis B carrier with family history
of HCC
0.2 Incidence higher than without family
history
African/North Am. Blacks>20 yrs 0.2 HCC occurs at a younger age
Bruix and Sherman, revised AASLD Practice Guideline 2011
Surveillance benefit uncertain: insufficient evidence
to recommend screening
Population group Threshold incidence for
efficacy of surveillance
(%/year)
Incidence of HCC
Cirrhosis due to non-alcoholic
steatohepatitis
??? ↑
Cirrhosis from autoimmune hepatitis 1.5 1.1%/yr
Cirrhosis from α1 antitrypsin deficiency ?? ??
Cirrhosis due to cystic fibrosis ?? ??
Bruix and Sherman, revised AASLD Practice Guideline 2011
Sensitivity of 6-month ultrasound to detect early
HCC (within Milan criteria)
Singal. APT 2009;30:37: Kim et al. Abstract aasld 2007:368
Algorithm for investigation of small nodules found on
screening in patients at risk for HCC
Suspicious Nodule
< 1cm > 1cm
Repeat imaging
every 3 mos
Dynamic imaging (4 phase CT scan, MRI)
Arterial enhancement and
Venous washout
Yes No
HCC Second imaging
or Biopsy
Bruix and Sherman
revised AASLD Practice Guideline
2011
2 yrs stable: assume benign disease
Key features of hepatocellular carcinoma